Customer stories

Dr. Andrew Magis in his own words, “The promise of proteomics: Transforming healthcare from treatment to disease prevention”

In a recent editorial article with SelectScience, Dr. Magis describes how his team is using longitudinal proteomics measurements to identify early signals and transition ...

View from the inside – SCALLOP pQTL CVD I study

SCALLOP founder, Anders Mälarstig, talks about the consortium’s first major combined study, which was recently made available on bioRxiv

Systems-level immunomonitoring of severe COVID-19

A longitudinal, systems-level approach characterizes cellular and protein immune responses in severe COVID-19, and during the recovery phase following severe disease.

SCALLOP publication in Nature Metabolism

SCALLOP consortium study in Nature Metabolism identifies protein quantitative trait loci (pQTL) for 90 cardiovascular proteins in over 30,000 individuals.

Immune system development in children – Petter Brodin

Petter Brodin talks about his landmark study (Olin et al, 2018), published in Cell, "Stereotypic immune system development in newborn children"

Protein biomarkers of COVID-19 pathophysiology (Radboud UMC)

A team from the Netherlands used targeted proteomics to find inflammatory and other biomarkers that characterize COVID-19 and the severity of the disease.

A rare but severe complication in children with COVID-19

A study by Petter Brodin's group at the Karolinska Institute sheds new light on Inflammatory Syndrome in Children (MIS-C). The results were published in Cell.

Longitudinal COVID-19 proteomics study from MGH

Olink is immensely proud of our contribution to one of the largest longitudinal COVID-19 studies together with the prestigious Massachusetts General Hospital (MGH).

Heart to heart – Faiez Zannad in his own words

Professor Faiez Zannad, one of the world’s foremost researchers in the area of heart failure, talks about his work, and the importance of protein biomarkers in his field